Sublingual administration of furosemide: new application of an old drug.

BACKGROUND In patients with decompensated heart failure, absorption of orally administered furosemide may be delayed, possibly leading to impaired pharmacodynamic effects. Sublingual administration may represent an alternative in such situations. METHODS In a crossover study including 11 healthy men, 20 mg furosemide was administered intravenously, orally and sublingually on three different days. Pharmacokinetics and pharmacodynamics were assessed from repeated blood and urine samples. RESULTS Compared with oral administration, sublingual administration was associated with 43% higher C(max)[difference 215 ng ml(-1), 95% confidence interval (CI) 37, 392], a higher urinary recovery (8.9 vs. 7.3 mg, difference 1.6 mg, 95% CI 0.3, 2.9), an 28% higher AUC (difference 328 ng h(-1) ml(-1), 95% CI 24, 632) and a higher bioavailability of furosemide (59 vs. 47%, difference 12.0%, 95% CI -1.2, 25.2). Sodium excretion was higher after sublingual compared with oral administration (peak excretion rate 1.8 vs. 1.4 mmol min(-1), P < 0.05), whereas urine volume did not differ significantly between the two application modes. In comparison, intravenous administration showed the expected more rapid and intense response. CONCLUSION Sublingually administered furosemide tablets differ in certain kinetic and dynamic properties from identical tablets given orally. Sublingual administration of furosemide may offer therapeutic advantages in certain groups of patients.

[1]  L. Paalzow,et al.  Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis , 2004, European Journal of Clinical Pharmacology.

[2]  G. Dehmer,et al.  Absorption and disposition of furosemide in congestive heart failure. , 1982, Kidney international.

[3]  Karl Swedberg,et al.  Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. , 2005, European heart journal.

[4]  A. Grahnén,et al.  Implications of intraindividual variability in bioavailability studies of furosemide , 2004, European Journal of Clinical Pharmacology.

[5]  W. L. Chiou,et al.  Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism , 1983, Journal of Pharmacokinetics and Biopharmaceutics.

[6]  D. Brater,et al.  Bumetanide and furosemide in heart failure. , 1984, Kidney international.

[7]  D. Brater,et al.  Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure , 1995, Clinical pharmacology and therapeutics.

[8]  L. Benet,et al.  Furosemide pharmacokinetics and pharmacodynamics in health and disease—An update , 1989, Journal of Pharmacokinetics and Biopharmaceutics.

[9]  W. Barron,et al.  Effect of food on the absorption of frusemide and bumetanide in man. , 2003, British journal of clinical pharmacology.

[10]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[11]  J. V. Nixon,et al.  Furosemide absorption altered in decompensated congestive heart failure. , 1985, Annals of internal medicine.

[12]  M. Murray,et al.  Variable Furosemide Absorption and Poor Predictability of Response in Elderly Patients , 1997, Pharmacotherapy.

[13]  Jie Zhang,et al.  Oral Mucosal Drug Delivery , 2002, Clinical pharmacokinetics.

[14]  S. Krähenbühl,et al.  Determination of furosemide in plasma and urine using monolithic silica rod liquid chromatography. , 2006, Journal of pharmaceutical and biomedical analysis.